New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 14, 2013
05:55 EDTCBSH, CBSH, FRX, FRX, IRWD, IRWD, LEN, LEN, MBWM, MBWMCompanies reporting Before the Market Open on Tuesday
Notable companies reporting before the opening bell on Tuesday include Commerce Bancshares (CBSH), Forest Laboratories (FRX), Ironwood Pharmaceuticals (IRWD), Lennar Corp (LEN), and Mercantile Bank (MBWM).
News For CBSH;FRX;IRWD;LEN;MBWM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
10:22 EDTMBWMMercantile Bank upgraded to Outperform from Market Perform at Fig Partners
Subscribe for More Information
October 21, 2014
06:06 EDTMBWMMercantile Bank reports Q3 EPS adjusted 40c, consensus 42c
Subscribe for More Information
October 20, 2014
08:08 EDTIRWDIronwood presents IW-9179 Phase IIa clinical study data
Subscribe for More Information
07:51 EDTLENLennar initiated with a Buy at Buckingham
Target $50.
October 16, 2014
15:10 EDTIRWDAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
08:02 EDTIRWDIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
October 15, 2014
07:05 EDTCBSHCommerce Bancshares reports Q3 EPS 72c, consensus 71c
Reports Q3 return on average assets 1.2%, Q3 return on average equity 12.3%. For the current quarter, the return on average assets totaled 1.20%, the return on average common equity was 12.3%, and the efficiency ratio was 60.6%. Net loan charge-offs for the current quarter totaled $7.7 million, compared to $7.6 million in the previous quarter. During the current quarter, the provision for loan losses totaled $7.7 million and matched net loan charge-offs. Total assets at September 30, 2014 were $22.7 billion, total loans were $11.4 billion, and total deposits were $18.6 billion.
October 14, 2014
15:29 EDTCBSHNotable companies reporting before tomorrow's open
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use